Clinical trials: Stage II Breast Cancer
Metastatic Breast Cancer
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
The purpose of this study is to determine if acquired hormone therapy resistance can be reversed by Avastin (Bevacizumab), as measured by time to disease progression and evaluate toxicity of the combination of hormone treatment…
- Trial name
- NCT00240071
- Testing
- Avastin, Hormonal therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes.
- Trial name
- NCT01439711
- Testing
- letrozole, MRI, conventional surgery
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Neutropenia
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This is a randomized open label dose finding study to evaluate the efficacy and safety of F-627 on women with Stage I-IV breast cancer receiving chemotherapy treatment.
- Trial name
- NCT01648322
- Testing
- F-627, Neulasta® (pegfilgrastim)
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- EVIVE Biotechnology
Breast Cancer
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone receptor positive breast cancer.
- Trial name
- NCT03051659
- Testing
- Eribulin Mesylate, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Study of Stereotactic Radiotherapy for Breast Cancer
This is a Phase II trial of preoperative stereotactic radiation to the breast for low risk breast cancer.
- Trial name
- NCT03043794
- Testing
- Stereotactic Body Radiation Therapy SBRT
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Male Breast Carcinoma, Recurrent Breast Carcinoma
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
This phase II trial studies how well giving azacitidine and entinostat work in treating patients with advanced breast cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor…
- Conditions
- Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01349959
- Testing
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Neoadjuvant GW572016 to Treat Breast Cancer
We want to learn whether GW572016 is effective in breast cancers that have HER2.
- Trial name
- GW (NCT00206427)
- Testing
- GW572016, lapatinib
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Baylor Breast Care Center
Neoplasms, Breast
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
This was a multicenter, open-label, Phase II study in subjects with Human epidermal growth factor receptor (HER2)-positive metastatic breast cancer who received at least 2 prior lines of anti-HER2-targeted therapies of which at…
- Trial name
- NCT02213042
- Testing
- Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
- Where
- 51 sites in United States, Argentina and 10 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
In this phase II trial the investigators propose to evaluate ixabepilone in combination with carboplatin and trastuzumab as neoadjuvant therapy in locally advanced breast cancer patients.
- Trial name
- NCT00821886
- Testing
- Ixabepilone, Trastuzumab, Carboplatin
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Melanoma, Gastrointestinal Cancer
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Background: Exomes are the parts of deoxyribonucleic acid (DNA) that make proteins. Researchers are finding a way to read the letters in the exome. Incorrect letters are called mutations. Tumors contain specific mutations.
- Conditions
- Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT03300843
- Testing
- Peptide loaded dendritic cell vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Neoplasm Metastasis
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Primary Objectives: 1. To identify the optimal dose and pharmacokinetics of RAD001 in combination with trastuzumab in a Phase I trial 2.
- Trial name
- NCT00317720
- Testing
- Trastuzumab, RAD001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms
Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer
This is a phase II, open-label, multicenter, pilot study of the safety and efficacy of two Docetaxel-based regimens plus bevacizumab for the adjuvant treatment of participants with node positive or high risk node negative breast…
- Trial name
- NCT00446030
- Testing
- Docetaxel, Doxorubicin, Carboplatin
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Sanofi
Breast Neoplasms
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and…
- Trial name
- NCT01723774
- Testing
- PD0332991, Anastrozole, Goserelin
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Washington University School of Medicine
Metastatic Breast Cancer
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer.
- Trial name
- NCT00759642
- Testing
- lapatinib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer, Stage I Breast Cancer
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines.
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT02096588
- Testing
- Simvastatin, Doxorubicin/cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Breast Cancer
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Doxorubicin has been an integral part of the treatment of women with breast cancer for many years. Since amrubicin may have more activity than doxorubicin, as well as less cardiotoxicity, evaluation of amrubicin in the treatment…
- Trial name
- NCT01033032
- Testing
- Amrubicin
- Where
- 16 sites in United States
- Volunteers
- 78 people
- Sponsor
- SCRI Development Innovations, LLC